Paid Clinical Trials in Paramus, NJ
As of August 2026, 45 paid clinical trials are recruiting in Paramus, New Jersey. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Paramus offers studies at sites including The Valley Hospital - Luckow Pavilion for conditions such as Acute Myeloid Leukemia, Carcinoma, Non-Small Cell Lung, Stage IIIB Lung Cancer AJCC v8, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Paramus
Trials by drug in Paramus
Filter results
Newly added in Paramus
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
42 clinical trials
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
Prevail Global Study
Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
E-Mindfulness Approaches for Living After Breast Cancer
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Repeatable Evaluation of Functional Intra-procedural Signals for Effect in Pulsed Field Ablation REFINE-PFA
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Top Research Study Locations in Paramus
Researchers run research studies in Paramus, NJ at 16 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| The Valley Hospital - Luckow Pavilion | Acute Myeloid Leukemia, Stage IIIB Lung Cancer AJCC v8, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | 17 |
| The Valley Hospital | Atrial Fibrillation, Aortic Stenosis, Coronary Artery Disease | 7 |
| Valley Health System | Acute or Chronic Coronary Artery Disease, Non-obstructive Coronary Disease, Ovarian Cancer | 3 |
| John Theurer Cancer Center at From Road | Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Leiomyosarcoma | 2 |
| Valley Health Systems - Ridgewood Campus | Squamous Non-small Cell Lung Cancer, Lymphoma, Large B-Cell, Diffuse | 2 |
| Alpine Learning Group | Autism Spectrum Disorder | 1 |
| Hackensack University Medical Center at Paramus | Acute Ischemic Stroke, Cerebral Stroke | 1 |
| Hackensack University Medical Center;Department of Neurology, Neuroscience Institute | Parkinson's Disease | 1 |
| North East Regional Surgical Center | Lumbar Spinal Stenosis | 1 |
| The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion | Non-small Cell Lung Cancer | 1 |
| The Valley Hospital Inc. | Melanoma | 1 |
| The Valley Hospital Paramus | Heart Failure, Obesity | 1 |
| The Valley Hospital, Inc | B Cell Lymphoma, Mantle Cell Lymphoma | 1 |
| The Valley Hospital, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 1 |
| The Valley Hospital-Luckow Pavilion | Cancer Metastatic, Metastatic Solid Tumor | 1 |
| Valley - Mount Sinai Comprehensive Cancer Care | HPV-positive Oropharyngeal Squamous Cell Carcinoma | 1 |
Active & Upcoming Studies in Paramus (2026)
Recruiting trials in Paramus grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (30 active studies)
- Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers · Phase 1, Phase 2 · Pfizer
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer · Phase 3 · National Cancer Institute (NCI)
Cardiovascular (6 active studies)
Diabetes & metabolic (2 active studies)
Mental health & behavior (1 active study)
- E-Mindfulness Approaches for Living After Breast Cancer · Phase 3 · NRG Oncology
Neurology & pain (1 active study)
- Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke · Phase 3 · Pharmazz, Inc.
Common conditions studied in Paramus
- Acute Myeloid Leukemia (4 active studies)
- Carcinoma, Non-Small Cell Lung (3 active studies)
- Stage IIIB Lung Cancer AJCC v8 (3 active studies)
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm (2 active studies)
- Acute Myeloid Leukemia Post Cytotoxic Therapy (2 active studies)
- Acute Myeloid Leukemia, Myelodysplasia-Related (2 active studies)
Leading research sponsors in Paramus
- National Cancer Institute (NCI)
- NRG Oncology
- AstraZeneca
- Alliance for Clinical Trials in Oncology
- Daiichi Sankyo
Frequently asked questions
How many paid clinical trials are currently recruiting in Paramus?
There are approximately 45 recruiting clinical trials in Paramus, New Jersey listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Paramus pay participants?
Most recruiting trials in Paramus compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Paramus?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Paramus?
The most common conditions under active study in Paramus include Acute Myeloid Leukemia (4), Carcinoma, Non-Small Cell Lung (3), Stage IIIB Lung Cancer AJCC v8 (3), Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Paramus?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Paramus on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Paramus?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Paramus?
Recruiting research sites in Paramus include The Valley Hospital - Luckow Pavilion, The Valley Hospital, Valley Health System, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Paramus right now?
The largest active categories in Paramus are Cancer & tumors (30), Cardiovascular (6), Diabetes & metabolic (2). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.